An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Recruiting · NCT07206056 · Registry updated 2026-10-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | Progressive Metastatic Castrate Resistant Prostate Cancer | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07206056 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cleveland Clinic Foundation | Cleveland | United States | 370 |
| Duke University Medical Center | Durham | United States | 505 |
| Emory University | Atlanta | United States | 27 |
| Fred Hutchinson Cancer Research Center | Seattle | United States | 4 |
| Mass General Hospital | Boston | United States | 14 |
| Sarah Cannon Research Institute | Jacksonville | United States | 1 |
| Sarah Cannon Research Institute | Denver | United States | 16 |
| Wichita Urology Group PA | Wichita | United States | 2 |